Display options
Cite
Jayash SN, Hashim NM, Misran M, et al. In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications. PeerJ. 2016;4:e2229doi: 10.7717/peerj.2229.
Jayash, S. N., Hashim, N. M., Misran, M., & Baharuddin, N. A. (2016). In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications. PeerJ, 4e2229. https://doi.org/10.7717/peerj.2229
Jayash, Soher Nagi, et al. "In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications." PeerJ vol. 4 (2016): e2229. doi: https://doi.org/10.7717/peerj.2229
Jayash SN, Hashim NM, Misran M, Baharuddin NA. In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications. PeerJ. 2016 Aug 23;4:e2229. doi: 10.7717/peerj.2229. eCollection 2016. PMID: 27635307; PMCID: PMC5012333.
Copy Download .nbib Format: NLM
Share it on

PeerJ. 2016 Aug 23;4:e2229. doi: 10.7717/peerj.2229. eCollection 2016.

In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications.

PeerJ

Soher Nagi Jayash, Najihah M Hashim, Misni Misran, N A Baharuddin

Affiliations

  1. Department of Restorative Dentistry, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.
  2. Department of Pharmacy, Faculty of Medicine, University of Malaya,Kuala Lumpur,Malaysia; Centre For Natural Products And Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya,Kuala Lumpur,Malaysia.
  3. Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.

PMID: 27635307 PMCID: PMC5012333 DOI: 10.7717/peerj.2229

Abstract

BACKGROUND: The receptor activator of nuclear factor kappa-B (RANK)/RANK ligand/osteoprotegerin (OPG) system plays a critical role in bone remodelling by regulating osteoclast formation and activity. OPG has been used systemically in the treatment of bone diseases. In searching for more effective and safer treatment for bone diseases, we investigated newly formulated OPG-chitosan complexes, which is prepared as a local application for its osteogenic potential to remediate bone defects.

METHODS: We examined high, medium and low molecular weights of chitosan combined with OPG. The cytotoxicity of OPG in chitosan and its proliferation in vitro was evaluated using normal, human periodontal ligament (NHPL) fibroblasts in 2D and 3D cell culture. The cytotoxicity of these combinations was compared by measuring cell survival with a tetrazolium salt reduction (MTT) assay and AlamarBlue assay. The cellular morphological changes were observed under an inverted microscope. A propidium iodide and acridine orange double-staining assay was used to evaluate the morphology and quantify the viable and nonviable cells. The expression level of osteopontin and osteocalcin protein in treated normal human osteoblast cells was evaluated by using Western blot.

RESULTS: The results demonstrated that OPG in combination with chitosan was non-toxic, and OPG combined with low molecular weight chitosan has the most significant effect on NHPL fibroblasts and stimulates proliferation of cells over the period of treatment.

Keywords: Bone; Chitosan; Normal human osteoblast; Normal human periodontal ligament fibroblast; Osteoproteogerin

Conflict of interest statement

The authors declare there are no competing interests.

References

  1. J Periodontal Res. 2011 Apr;46(2):153-7 - PubMed
  2. J Oral Maxillofac Surg. 2011 Nov;69(11):e446-55 - PubMed
  3. J Biomed Mater Res A. 2010 Apr;93(1):107-14 - PubMed
  4. J Stem Cells Regen Med. 2011 Apr 01;7(1):54-6 - PubMed
  5. J Periodontol. 2000 Mar;71(3):418-24 - PubMed
  6. Cancer. 2003 Feb 1;97(3 Suppl):887-92 - PubMed
  7. J Vis Exp. 2009 Dec 17;(34):null - PubMed
  8. Endocrinology. 2013 Feb;154(2):773-82 - PubMed
  9. J Cell Biochem. 2007 Aug 15;101(6):1370-83 - PubMed
  10. Endocrinology. 2001 Oct;142(10):4295-304 - PubMed
  11. Cancer Res. 2003 Mar 1;63(5):912-6 - PubMed
  12. J Bone Miner Res. 2001 Feb;16(2):348-60 - PubMed
  13. Cancer Res. 2007 Aug 1;67(15):7308-18 - PubMed
  14. Dent Mater J. 2013;32(2):233-40 - PubMed
  15. J Endocrinol. 1998 Sep;158(3):377-88 - PubMed
  16. J Biomater Appl. 2014 Mar;28(7):1060-8 - PubMed
  17. Biomaterials. 2002 Dec;23(23):4609-14 - PubMed
  18. Exp Oncol. 2012 Oct;34(3):160-4 - PubMed
  19. Endocrinology. 1999 Sep;140(9):4367-70 - PubMed
  20. Dent Traumatol. 2010 Jun;26(3):271-5 - PubMed
  21. Biomaterials. 1994 Oct;15(13):1075-81 - PubMed
  22. Cell. 2007 Aug 24;130(4):601-10 - PubMed
  23. PLoS One. 2013;8(1):e53708 - PubMed
  24. Cell Death Differ. 2014 Sep;21(9):1350-64 - PubMed
  25. J Biomed Mater Res A. 2013 Oct;101(10 ):2974-83 - PubMed
  26. Pharm Res. 1998 Sep;15(9):1326-31 - PubMed
  27. Clin Exp Immunol. 2002 Nov;130(2):338-44 - PubMed
  28. J Periodontal Res. 2015 Apr;50(2):211-9 - PubMed
  29. Cell Transplant. 2004;13(1):15-25 - PubMed
  30. Int J Biol Macromol. 2011 Nov 1;49(4):573-9 - PubMed
  31. J Biomed Mater Res B Appl Biomater. 2014 Jul;102(5):913-21 - PubMed
  32. Cytokine Growth Factor Rev. 2013 Oct;24(5):401-9 - PubMed
  33. Eur J Orthod. 1997 Dec;19(6):615-21 - PubMed
  34. J Ovarian Res. 2012 Nov 15;5(1):34 - PubMed
  35. Clin Exp Immunol. 2004 Aug;137(2):430-6 - PubMed
  36. J Biomater Sci Polym Ed. 2007;18(2):147-63 - PubMed
  37. J Periodontol. 2007 Jul;78(7):1300-8 - PubMed
  38. Cancer Res. 2002 Mar 15;62(6):1619-23 - PubMed
  39. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2007 Apr;24(2):340-4 - PubMed
  40. J Clin Periodontol. 2007 May;34(5):370-6 - PubMed

Publication Types